Robin joined Myricx in Nov 2019 as chief development officer and became CEO in August 2022.

Robin joined Myricx from GSK, where he held several research Exec roles (2007-2019), his final role was SVP Drug Design and Selection, with global responsibility for small molecule and biopharm discovery platforms. Robin served as a member of GSK’s Discovery Investment Board, Technology Investment Board and co-chaired the target selection committee.

Prior to GSK, Robin was VP of drug discovery at Astex Therapeutics (1999-2007), with responsibility for internal and partnered drug discovery programs.

Robin holds a chemistry degree from Imperial College London (1981) and completed his PhD studies in total synthesis at Northwestern University, Chicago (1984). Robin then returned to the UK to start his industrial research career at ICI agrochemicals before joining Glaxo in 1989 to focus on drug discovery.

Robin has co-authored and published 50 papers and patents and contributed to numerous discovery programs (cancer and respiratory) that have progressed into the clinic and two of which went on to become launched drugs.

Robin has a long-standing interest in novel drug discovery platforms that have the potential to reduce attrition rates and therefore increase R&D productivity.